World economy will lose trillions if poor countries shorted on vaccines: OECD - Medicine Hat NewsMedicine Hat News medicinehatnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicinehatnews.com Daily Mail and Mail on Sunday newspapers.
Credit: Courtesy UHN
TORONTO (February 5, 2021) - A clinical study led by Dr. Jordan Feld, a liver specialist at Toronto Centre for Liver Disease, University Health Network (UHN), showed an experimental antiviral drug can significantly speed up recovery for COVID-19 outpatients - patients who do not need to be hospitalized.
This could become an important intervention to treat infected patients and help curb community spread, while COVID-19 vaccines are rolled out this year. This treatment has large therapeutic potential, especially at this moment as we see aggressive variants of the virus spreading around the globe which are less sensitive to both vaccines and treatment with antibodies, says Dr. Feld, who is also Co-Director of the Schwartz Reisman Liver Research Centre and the R. Phelan Chair in Translational Liver Research at UHN.
Dr. Alan Bernstein says the COVID-19 pandemic should serve as a wake-up call. Mike Blanchfield, Canadian Press
ASSOCIATED PRESS
A dose of the Pfizer-BioNTech COVID-19 vaccine is prepared by Pharmacy Technician Supervisor Tamara Booth Rumsey at The Michener Institute in Toronto on Jan. 4, 2021.
OTTAWA A leading Canadian health expert on the federal government’s COVID-19 Task Force says the pandemic should be viewed as a wake-up call for Canada to create its own domestic vaccine manufacturing capacity.
Dr. Alan Bernstein says that with new variants of the novel coronavirus emerging, Canadians might need multiple vaccines for several years.
“The government’s made hints of doing it. But I think the sooner we get on with it, the better,” Bernstein, who is also the head of the Canadian Institute for Advanced Research (CIFAR), said in an interview Friday.